Israel - ebraică - Ministry of Health

takeda israel ltd - velaglucerase alfa - lyophilized powder for infusion - velaglucerase alfa 400 u/vial - velaglucerase alfa - velaglucerase alfa - vpriv is a hydrolytic glucocerebroside – specific enzyme indicated for the long term replacement therapy (ert) for pediatric and adult patients with type 1 gaucher disease.

Israel - ebraică - Ministry of Health

neopharm cure (2005) ltd - midazolam as hydrochloride - תמיסה לחלל הפה - midazolam as hydrochloride 10 mg - midazolam

Israel - ebraică - Ministry of Health

neopharm cure (2005) ltd - midazolam as hydrochloride - תמיסה לחלל הפה - midazolam as hydrochloride 2.5 mg - midazolam

Israel - ebraică - Ministry of Health

neopharm cure (2005) ltd - midazolam as hydrochloride - תמיסה לחלל הפה - midazolam as hydrochloride 5 mg - midazolam

Israel - ebraică - Ministry of Health

neopharm cure (2005) ltd - midazolam as hydrochloride - תמיסה לחלל הפה - midazolam as hydrochloride 7.5 mg - midazolam

Israel - ebraică - Ministry of Health

trimaco medical division ltd. - רופא - משתלים ,מכשור, לניתוחים אורטופדיים

Israel - ebraică - Ministry of Health

trimaco medical division ltd. - רופא - משתלים ומכשור לניתוחים אורטופדיים, נוירוכירורגיה

Israel - ebraică - Ministry of Health

trimaco medical division ltd. - רופא

Israel - ebraică - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

Israel - ebraică - Ministry of Health

astrazeneca (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - ספריי לאף - b/phuket/3073/2013 (b/yamagata lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/darwin/9/2021 (h3n2)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 7 ±0.5 log10 ffu^a / 0.2 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - flumist quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses ad type b viruses contained in the vaccine. flumist quadrivalent is approved for use in persons 2 through 49 years of age.